Navigation Links
Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
Date:10/8/2008

ich benign tumors grow on the larynx, vocal cords and trachea. Combined, GW and RRP affect more than 2.5 million people worldwide and represent an estimated global market potential of more than $1 billion. There are currently no approved cures for either condition. Early preclinical data suggest that Hsp 6/11 has the ability to elicit strong T-cell responses against HPV types 6 and 11 target antigens. Next steps for Hsp 6/11 include finalizing manufacturing and formulation protocols and filing an IND. Partnering or adequate financing are required for these efforts to continue.

Corporate Restructuring and Focus on Corporate Development Efforts

With the support of a unanimous decision by Nventa's board of directors, the company will undertake a corporate restructuring designed to extend the company's financial resources and increase the focus on corporate development efforts surrounding the company's core assets. Key elements of the restructuring include:

-- A sixty percent reduction of staff from 13 to 5. As part of this

reduction, Richard B. Lai Fatt, Ph.D., vice president of corporate

development and David Duncan, Jr., vice president of finance, will be

leaving the company. Peter Emtage, Ph.D. will remain as vice

president of research and development. Concurrent with the

restructuring, board members, Jay M. Short, Ph.D., Joann Data, M.D.,

Ph.D., Gordon Busenbark, and Sandford D. Smith, as well as all members

of the scientific advisory board, will be stepping down. Robert

Rieder will become chairman of the board and John Varian will continue

as the audit committee chair.

-- A reduction of annualized cash burn of approximately 30 percent.

-- An increased focus of corporate resources toward monetizing the

company's core assets. As part of this, the company will expand its

corporate development efforts for the pur
'/>"/>

SOURCE Nventa Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. CardioDynamics Provides 2007 Shareholder Meeting Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 In response ... FedEx, UPS and The US Postal Service to ... classified as ,select agents, by the CDC, Marken ... handling these sensitive shipments. Marken uses ... regulations, trained and certified personnel to ensure the ...
(Date:8/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended June 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... our Oral Amp B program, rapidly advancing towards ... Andrew Rae , President & CEO of iCo ...
(Date:8/26/2015)... 26, 2015  The Diabetes Research Institute (DRI), ... Miami Miller School of Medicine, announced today that ... test for the first time a novel transplant ... FDA approved Phase I/II study builds upon decades ... an important first step toward the development of ...
(Date:8/26/2015)... August 26, 2015 Israel Proves Its Place ... 1 st place  Wayerz comes in 5 th ... Israel by venture capital fund JVP, with Chinese consulting ... China , Israel , ... Impressive achievement for the Israeli representatives in the final ...
Breaking Biology Technology:Marken Ensures Safe Transportation Of Select Agents And Toxins 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
... Deliver Electronic X-ray-Based, Therapy Directly to ... SUNNYVALE, Calif., March 17 Xoft, ... clearance from the U.S. Food & Drug,Administration ... a,proprietary technology platform designed to deliver localized,non-radioactive, ...
... poised to ... MENLO PARK, Calif., March 17 Apieron, Inc., ... has received,clearance to market by the U.S. Food and ... nitric oxide (eNO), which is a,well-established indicator of airway ...
... -, SAN DIEGO, Calif., March 17 BioMed ... its board of directors has,declared a first quarter 2008 ... increase over the company,s previous quarterly dividend of $0.31,per ... dividend,of $1.34 per common share., BioMed also announced ...
Cached Biology Technology:FDA Clears Expanded Use of Xoft's Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications 2Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management 2Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management 3BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend 2
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
(Date:7/31/2015)... July 31, 2015 The 10 th International ... by BGI from October 22-25, 2015, in Shenzhen ... conference is celebrating its 10 th anniversary this year. Since ... world,s most influential annual meetings in the ,omics, fields, and ... gatherings. ICG-10 focuses on recent breakthroughs and ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... The Human Microbiome Project has awarded more than $42 million to ... live in or on our bodies affect our health, the National ... microbiome is all the microorganisms that reside in or on the ... in 2007 as part of the NIH Common Fund,s Roadmap for ...
... 2009 Chronix Biomedical today reported that a new ... diagnostic and prognostic utility of using circulating fragments of ... fragments, referred to as serum DNA, are released into ... process. Chronix Biomedical has developed proprietary technology that can ...
... , -- Results from Parascript SignatureXpert confirm that signatures ... Court of Moscow to initiate forensic examination and expert ... , BOULDER, Colo., June 22 Parascript, ... today announced that it has partnered with the Moscow ...
Cached Biology News:NIH expands Human Microbiome Project; funds sequencing centers and disease projects 2NIH expands Human Microbiome Project; funds sequencing centers and disease projects 3NIH expands Human Microbiome Project; funds sequencing centers and disease projects 4NIH expands Human Microbiome Project; funds sequencing centers and disease projects 5Study shows Chronix technology using serum DNA can identify early presence of disease 2Parascript Signature Verification Technology Used by Moscow Law Firm to Detect Signature Fraud in $160,000 Debt Collection Case 2Parascript Signature Verification Technology Used by Moscow Law Firm to Detect Signature Fraud in $160,000 Debt Collection Case 3
Liquid. PBS containing 10 mM NaN 3 . AVOID FREEZE/THAW CYCLES. Recognizes α1, 2, 3, 5, 6 and 7 subunits of 20S proteasome. ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Goat polyclonal to Lipocalin 2...
Biology Products: